Drug Profile
FA31A
Latest Information Update: 06 Aug 2002
Price :
$50
*
At a glance
- Originator Pharmacia Corporation
- Class Disease-modifying antirheumatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 05 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
- 07 Apr 1998 Phase-II clinical trials for Rheumatoid arthritis in European Union (Unknown route)